Navigation Links
Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
Date:1/3/2008

CRANBURY, N.J., Jan. 2 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the 26th Annual JPMorgan Healthcare Conference in San Francisco, CA on Monday, January 7, 2008 at 11:30 am (Pacific Standard Time) at the Westin St. Francis Hotel.

The presentation will be webcast live and may be accessed by visiting Amicus' website at http://www.amicustherapeutics.com. A replay of the webcast will also be available on the Company's website until January 22, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company has completed Phase 1 clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across ... virus, select Meijer pharmacies in Michigan ... to eligible patients, enabling Meijer pharmacists to administer tests and, ... set by a physician participating in the study. ...
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... George Products Company, Inc. has announced the addition ... OASIS Inspection Systems. Florida Metrology, based ... OASIS Inspection Systems is a line of highly accurate ... control departments across the United States. Tim Row of ...
... Sutro Biopharma, a biopharmaceutical company developing both ... properties, today announced that it has appointed Trevor ... Hallam will lead Sutro,s ongoing efforts in the ... platform for the research and development of novel ...
Cached Medicine Technology:Florida Metrology To Distribute OASIS Inspection Systems 2Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer 2
(Date:4/18/2014)... release is available in French . ... revolutionize surgical practice and regenerative medicine. A team led ... Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the ... 13), has just demonstrated that the principle of adhesion ... vivo to repair soft-tissue organs and tissues. This easy-to-use ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2
... , BETHEL, Conn., Dec. 4 MedClean Technologies, Inc. (OTC Bulletin ... stock purchase agreement with Socius Capital Group, LLC, a Delaware limited ... LLC. Pursuant to the Purchase Agreement, MedClean will receive up to ... up to 750 shares of its Series C Preferred Stock, in ...
... , UNION, N.J., Dec. 4 ... its specialty anatomic pathology services with the launch of ... company,s expansion from a regional laboratory to a leading ... full range of specialties including gastroenterology, urology and now ...
... , OKLAHOMA CITY, Dec. 4 PD-Rx Pharmaceuticals, Inc. (Pink Sheets: ... September 30, 2009, a 24% decrease over the same period last ... $133,681 and $80,402, respectively, each a 70% decrease over the same ... pharmacy sector sales. This trend is expected to continue throughout ...
... SEATTLE, Dec. 4 The National Cancer Institute has awarded a ... become the nation,s sole operator of its Cancer Information Service Contact ... Hutchinson Center - nearly tripling the size of its current CIS ... scheduled for March 15, 2010. The Seattle CIS center will remain ...
... School of Medicine (BUSM) researchers at the Slone Epidemiology Center ... have a reduced incidence of uterine leiomyomata (fibroids). This report, ... current issue of the American Journal of Epidemiology . ... are two to three times more common among black women ...
... ... support Joint Commission initiative to establish standards for language access in healthcare organizations. ... ... information, drug data solutions, and patient education materials for healthcare institutions, understands the ...
Cached Medicine News:Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 3Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3Health News:PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings 2Health News:Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service 2Health News:Researchers find increased dairy intake reduces risk of uterine fibroids in black women 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 3
The Fathom Guidewire combines a nitinol hypotube distal segment with advanced microfabrication technology, creating a design that revolutionizes access of the most tortuous vasculature....
... (hepatitis C virus) is a Microparticle Enzyme ... anti-HCV IgG to HCV recombinant proteins in ... EDTA, sodium heparin, lithium heparin, sodium citrate ... with other laboratory results and clinical information, ...
... MasterControl architecture is the power behind ... provides all the essential building blocks ... management system to boost operational efficiency, ... with regulatory and quality standards. Click ...
... systems are automated, easy to operate and ... outside environment by flexible snap-seal pockets which ... viral contamination of the water. Offered in ... can also accommodate bags of various sizes. ...
Medicine Products: